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pathological environments and what is the mechanism and pathological relevance of this colocalization. We studied skin lesions from BD patients. Previous studies implicated Th1 cells promoting cytokine in skin lesions from BD patients [Melikoglu et al., 2006] . In the current investigation, we explored the phenotype and function of IL-17 -secreting T cells in BD and healthy skin, and the factors supporting their trafficking to and induction in lesional skin. Specifically, we show that IFN- is demonstrated as a potent promoter of IL-17 + T cell trafficking, induction, and function. Our observations support a model wherein Th1 and IL-17 + T cells mechanistically interact and collaboratively contribute to BD skin pathogenesis.
Materials and methods

Patients skin testing, and tissue samples
The study was approved by the Ethical Committee of our University. A total of 12 patients with active BD (3 females, 9 males) fulfilling the International Study Group Criteria for BD [ISG. 1990] were enrolled into this study. BD patients were aged: 39 years (range 26-47 years) and the mean disease duration were 76 months (range 10-132 months). Disease activity was evaluated according to published criteria [Lawton & Bhakta, 2004] . Of 12 patients, all had oral ulcerations, 8 had genital ulcers, 6 had erythema nodosum, 10 had papulopustular lesions, 8 had arthritis, 7 had uveitis, 6 had deep venous thrombosis, and 11 had a positive skin pathergy reaction (SPR). Consistent with previous published reports, there were no demographic or clinical differences discernible between BD patients with a positive or negative SPR in our study [Krause et al., 2000] . The skin lesions were scored [Diri et al., 2001] : 0 = no lesions; 1 = 1-5 lesions; 2 = 6-10 lesions; 3 = 11-15 lesions; 4 = 16-20 lesions; and 5 = more than 20 lesions. Table I describes BD patients with skin lesions. Patients were treated with steroids and colchicines. Seven donors of healthy human skin were included in this study. Punch-biopsy specimens (4 mm) were obtained from affected skin (pustular eruption) and were divided in two equal parts, one for T cell elution and one for RT-PCR analysis. All skin biopsy samples were obtained with a circular dermal punch after injection of 1% lidocaine solution into the hypodermis. Biopsy samples were snap frozen directly in liquid nitrogen for mRNA extraction and RT-PCR analysis.
Immune cell isolation
Single cell suspensions were prepared from PBMC and skin tissue samples. Skin biopsy samples were incubated in 50 U/ml dispase (BD Biosciences) at 37°C for 90 min. The skin portions were then cut into 1-mm pieces and digested in collagenase for 2 h at room temperature. Single cell suspensions of epidermal portions were generated by incubation in Cell Dissociation buffer (Invitrogen) at 37°C for 2 h. Skin explant cultures of T cells from skin biopsies were prepared as described by Clark et al. [Clark et al., 2006] . Immune cells including T cells and CD14 + or CD11c + myeloid APCs were enriched using paramagnetic beads (StemCell Technologies) and sorted from stained single cell suspensions using a high-speed cell sorter (FACSAria; BD Immunocytometry Systems) as described by Curiel et al [Curiel et al., 2003] . Cell purity was >98% as confirmed by flow cytometry (LSR II; BD Immunocytometry Systems). CD14 + or CD11c + myeloidAPCs were used to stimulate T cells as indicated.
APC activation and cytokine production
Fresh peripheral blood CD11c + APCs (0.5 x 10 6 /ml) were incubated for 72 h with or without recombinant human IFN- (200 ng/ml; R&D Systems). These cells were washed and used for T cell stimulation or activated for 12 h with LPS (1 µg/ml; Sigma-Aldrich) or incubated 3 days (1 x 10 6 cells/ml) in the presence of LPS to detect cytokine levels in supernatants. All Abs were from R&D Systems.
T cell culture system
Myeloid APCs were cocultured with peripheral blood T cells in ratios from 1:3 to 1:10 (0.5 x 10 6 T cells/ml) for 4 days in the presence of anti-CD3 (2.5 -5 µg/ml) and anti-CD28 (1.2 -2.5 µg/ml) mAbs (BD Biosciences). Different cytokines and neutralizing antibodies (Abs) or their combinations including IL-1 (2.5 ng/ml), IL-1 (2.5 ng/ml), IL-23 (10 ng/ml), anti-IL-4 (1 µg/ml), anti-IFN- (2 µg/ml), anti-IL-1 (1 µg/ml anti-IL-1R plus 1 µg/ml anti-IL-1) were used as indicated (all from R&D Systems). Cells were subjected to flow cytometric phenotyping, intracellular cytokine staining, and transcript detection by real-time PCR. Culture supernatants were collected for detection of IL-17 by ELISA (R&D Systems). For flow cytometry analysis, cells were first stained extracellularly with specific monoclonal antibodies (Abs), then fixed and permeabilized with Perm/Fix solution (eBioscience), and finally stained intracellularly with specific Abs against the indicated cytokines (BD Biosciences). Samples were acquired on a LSR II (BD Biosciences) and data were analyzed with DIVA software (BD Biosciences).
Migration assays
Migration assays were performed in a Transwell system with a polycarbonate membrane of 6.5 mm diameter with a 3-µm pore size as described by Curiel et al. [Curiel et al., 2004] . Purified T cell subsets were added to the upper chamber, and CCL20 (5 ng/ml; R&D Systems) was added to the lower chamber. After 4 h of incubation at 37°C, the phenotype and number of T cells in the upper and lower chambers was determined by FACS.
Quantification of gene expression
Quantitative real-time PCR was performed on control and lesional skin samples from 12 BD patients and 7 normal healthy controls as we have recently reported [Hamzaoui et al., 2008] . Quantification of gene expression in the cultured myeloid APCs was performed as described by Kryczek et al [Kryczek et al., 2007] . The gene transcripts were quantified in a MasterCycler RealPlex system (Eppendorf Scientific) and expressed as mRNA quantities normalized to GAPDH levels.
Immunohistochemistry
Skin biopsy samples were stained with anti-CD4 or anti-CD8 Ab as described [Hamzaoui et al., 2008] . The staining was detected using the one-step avidin-biotin complex technique (BD Pharmingen).
Statistical calculations
The Wilcoxon rank-sum test was used to determine pairwise differences and the 2 test used to determine differences between groups. A value for p < 0.05 was considered as significant. Differences in phenotype of T cell subsets were tested with the paired Student's t test.
Correlation was tested by Spearman's test. All statistical analysis was done on Statistical software (StatSoft).
Results
IL-17
+ T cells are increased in BD skin lesions We investigated the distribution of CD4 + and CD8 + IL-17 + T cells in BD-skin lesions and in healthy donors [ Figure 1A and Figure 1B ]. High levels of CD3 + IL-17 + T cells were observed in active BD compared to healthy control skin. The highest percentage of CD4 + and CD8 + IL-17 + T cells were observed in BD-skin lesions. Notably, we observed an increased number of CD8 + IL-17 + T cells in BD-skin [ Figure 1B ]. We further analyzed the expression of IFN- and IL-17 per single cell level. Interestingly, 40-60% IL-17 + T cells coexpressed IFN- in the BDskin [ Figure 1C ]. The data demonstrate the prevalence, phenotype, and distribution of IL-17 + T cells in patients with BD, and indicate that BD-skin lesions is an environment containing abundant IL-17 + T cells including Th17 cells and CD8 + IL-17 + T cells. 
IFN-+ T cells in patients with BD
As BD was related as Th1 disease, we examined the distribution of CD4 + , CD8 + , and IFN-+ T cells in BD-skin lesion. Consistent with previous reports Figure 2B ] were also detected in BD skin lesions compared to healthy controls. 
Myeloid APCs induce IL-17
+ T cells We sorted both CD14 + and CD11c + myeloid APCs from peripheral blood and skin lesions from BD patients and healthy donors [ Figure 3A ]. CD14+ and CD11c+ myeloid APCs induced similar levels of Th17 cells [ Figure 3B ]. Then we investigated the potential role for myeloid APCs in inducing IL-17 + T cells [ Figure 3C ]. Interestingly, APCs from BD peripheral blood and skin lesions were significantly more efficient than those from healthy donors in inducing IL-17 production [ Figure 3C ]. Myeloid APCs induced both CD4 + and CD8 + IL-17 + T cells [ Figure 3D ]. We performed similar experiments with responder T cells from normal donors and BD patients. Our data indicate that BD myeloid APCs potently induce IL-17 + T cells, and may thereby stimulate and maintain the IL-17 + T cell pool in BD patients. Figure 4A , B, and C]. We also conditioned peripheral blood myeloid APCs from BD patients with exogenous IFN-, and observed that IFN- was able to further enhance the ability of healthy controls and BD myeloid APCs to induce IL-17 -secreting T cells [ Figure 4 ]. The data suggest that IFN- released by BD T cells may condition myeloid APCs to induce IL-17 + T cells. 
CCR6+ IL-17
+ T cells and CCL20 in Behçet's disease We examined how IL-17 + T cells traffic to the BD skin environment. We found that CD4 + and CD8 + IL-17 + T cells derived from BD skin lesions highly expressed CCR6 [ Figure 5A and B]. We therefore asked whether IL-17 + T cells could migrate toward CCL20, the ligand for CCR6. We observed that T cells efficiently migrated in response to CCL20, and that the migrating cells were enriched for IL-17 + T cells (from 0.2% IL-17-cells in the upper chamber to 18% IL-17 + T cells in the lower chamber) [ Figure  5C ]. We further tested the role of IFN- in CCL20 production. We observed that IFN stimulated CCL20 production from CD11c + APCs [ Figure 5D ]. High levels of CCL20 mRNA were detected in lesional BD skin [ Figure 5E ]. The data suggest that IFN- derived from BD T cells induces CCL20 and promotes homing of IL-17 + T cells to the BD environment. In addition to CCR6, we observed that BD-IL-17 + T cells highly expressed CD103 as compared with IL-17-T cells [ Figure 5F ]. CD103 may play a specific role in IL-17 + T cell trafficking. 
Discussion
In this report we have investigated the phenotype and function of IL-17 + T cells in skin healthy controls and BD patients with skin lesions. We show that CD3 + T cells expressing IL-17 were increased in BD-skin lesions compared to skin biopsies from healthy controls. CD3 + IL-17 + T cells (Th17) are postulated to play a role in inflammatory/autoimmune pathogenesis [Wilson et al., 2007; Zaba et al., 2007; Murphy et al., 2003; Aggarwal et al., 2003] . Recent data from Melikoglu et al [Melikoglu et al., 2006] reported increased cytokines (IFN-, IL-12 p40, IL-15), chemokines (MIP3-, IP-10, Mig, and iTac), and adhesion molecules (ICAM-1, VCAM-1) in the skin of BD patients with SPR + but not in the skin of normal controls. These results suggested that BD patients experience marked cellular influx into the injury site, leading to an exaggerated lymphoid Th1-type response. Our results agree the inflammatory state in skin BD patient; our present results added a Th17-type response. We show that both CD4 + and CD8 + T cells express IL-17 in BD-skin lesions. We observed high levels of CD8 + IL-17 + T cells in the BD skin lesions. CD8 + IL-17 + T cells are ideally positioned to respond to potential keratinocyte autoantigens on HLA class I molecules. CD8 + IL-17 + T cells have been genetically implicated in skin lesions from autoimmune/inflammatory diseases [Nair et al., 206] . Our observations support the hypothesis that CD8 + IL-17 + T cells are critical mediators of the persistently altered epidermal growth and differentiation and the local inflammation that is characteristic of BD skin lesions. CD8 + IL-17 + T cells were observed in cancers [12] and in psoriasis . Our data provide the first evidence that CD8 + IL-17 + T cells are important in BD as observed in autoimmune/inflammatory diseases [Wilson et al., 2007] . The presence of CD8 + T cells is necessary for the epidermal hyperproliferative response [Conrad et al., 2007] . We characterized the phenotype of skin BD lesions IL-17 + T cells: CD103 + CCR6 + IL-17 + T cells are effector T cells often found in environments with chronic inflammation [Gudjonsson et al. 2004; Krolls et al., 2006] . IL-17 + T cells highly express CD103, which may facilitate trafficking of IL-17 + cells into inflammatory tissues [Conrad et al., 2007; Pauls et al., 2001] . We confirm that BD skin is an environment enriched with CCL20, and show that CCL20 is triggered by IFN- in myeloid APCs. We reported that BD Th1 cells are one of the major sources of IFN-, as reported recently [Hamzaoui et al., 2007] , and that IL-17 + T cells efficiently migrate toward a CCL20-enriched BD environment via CCR6. Our data lead us to propose a first mode of potential interaction between Th1 and IL-17 + T cells in BD: IFN- derived from Th1 cells promotes trafficking of IL-17 + T cells to the environment BD lesions through the induction and maintenance of local CCL20 production. Regarding the contribution of epidermal CD8 + IL-17 + cells to the pathogenesis of BD skin lesions, we have proved that CD4 + IL-17 + and CD8 + IL-17 + proliferate and secrete cytokines efficiently in response to CD3/TCR-mediated stimulation and to certain mediators. In Behcet's disease, high mRNA levels of IL-8, IFN-, IL-12, IL-10, and MCP-1were found in lesional skin and pathergy sites [Melikoglu et al., 2006] . CD4 + CD25 + regulatory T (Treg) cells were found increased in the peripheral circulation of BD patients [Hamzaoui, 2007] . Treg cells and interleukin 17 (IL-17)-producing T helper cells (TH17) carry out opposite functions, the former maintaining self-tolerance and the latter being involved in inflammation and autoimmunity [Deknuydt et al., 2009] . Several recent studies have indicated the existence of a close interplay between Treg and Th17 cells in regulating some autoimmune diseases. Whereas murine Treg cells suppress both Th1 and Th2 cells, in BD patients they enhance IL-17 secretion, likely through production of TGF- Veldhoen et al., 2006] . Interplay between Treg cells and CD4 + IL-17 + cells have to be investigated in BD patients [Hamzaoui et al., 2011a; 2011b] . Memory Treg actually showed a more pronounced proficiency to give rise to Th17 cells than conventional memory CD4 + T cells, suggesting that they may be at least partially committed towards the T H 17 differentiation pathway. This is consistent with the fact that memory Treg populations contain high proportions of cells expressing CCR6, the receptor of macrophage inflammatory protein3 (MIP-3/CCL20) that has been shown to characterize the T H 17 lineage [Acosta-Rodriguez et al., 2007; Tosello et al., 2008] . The findings reported in the present study have several implications. First, one can imagine a scenario in which, during skin BD inflammation, Treg cells stimulated by APC activated by microbial products participate to innate immunity and transiently down-regulate suppressor functions, to allow the development of adaptive immunity. In a second scenario, sustained induction of Treg into Th17 cells in vivo will likely occur under defined permissive conditions, such as those that have been reported to lead to autoimmune/inflammatory reactions including chronic inflammation in the presence of interleukin (IL)-1 and IL-2. IL-1 was highly expressed in BD [Bilginer et al., 2010; Kôtter et al., 2005] . There are <1% CD4 + and <0.5% CD8 + IL-17 + T cells in peripheral blood of healthy humans [Kryczek et al., 2007] . Peripheral blood of active BD patients exhibited high levels of Th17 cells in their peripheral circulation [Hamzaoui et al., 2002; Direskeneli et al.; Hamzaoui et al., 2011] and in cerebrospinal fluid [Hamzaoui et al., 2011] . High levels of Th17, CD4 + IL-17 + and CD8 + IL-17 + T cells are observed in BD inflammatory skin. How does this induction occur? In addition to migration from peripheral blood, IL-17 + T cells may be induced within the BD lesions environment. It has been reported that myeloid cell-derived genes contribute to pathogenic manifestations in inflammatory diseases [Haider et al., 2008; Szegedi et al., 2003] . We demonstrate that myeloid APCs including macrophages and myeloid dendritic cells potently induce human IL-17 + T cells. Our observation may also explain why IL-17 + T cells are often found in inflammatory tissues and organs. In support of this concept, we show that myeloid APCs isolated from BD patients potently stimulate IL-17 + T cells. Increased circulating IFN- [Szegedi et al.,2003 ] may activate circulating APCs, allowing them to enter tissue and promote expansion of IL-17 + T cells. Th1 cells can suppress Th17 cell differentiation through IFN- [Kolls et al., 2004; Weaver et al., 2006; Teunissen et al., 1998 ]. IFN- triggers myeloid APCs to produce IL-1 and IL-23, and in turn induce IL-17 + T cells . Our data therefore demonstrate the potential mode of interaction between Th1 and IL-17 + T cells in BD skin lesions: IFN- derived from Th1 cells promotes IL-17 + T cell development through IL-1 and IL-23 in the skin lesion environment in Behcet disease. Therefore, IFN- may possibly play dual roles in regulating the IL-17 + T cell pool: IFN- targets APCs to initiate and promote Th17 polarization [Teunissen et al., 1998; Kolls et al., 2004; Szabo et al., 1998 ] to suppress Th17 polarization. In summary, we show that IFN- may promote trafficking, induction, and function of IL-17 + T cells in patients with BD. This study clarify the interaction between Th1 and Th17 cells, challenges the view that Th1 cells suppress Th17 cell development, and suggests a collaborative contribution of Th1 and Th17 to autoimmune/inflammatory diseases. Ongoing research is addressing this aspect as well as attempting to define better whether CD8 + IL-17 + lymphocytes act as cytotoxic cells (Tc17 cells) which contribute to initiate, stabilize, or inhibit the BD process in the skin.
